The failure of antiangiogenic therapy in the treatment of metastatic breast cancer is due to the development of resistance to inhibition of vascular endothelial growth factor (VEGF), and our inability to identify patients most likely to respond to such therapies. To elucidate the factors underlying 'antiangiogenic resistance' and develop translational biomarkers for identifying resistance in patients, it is necessary to relate molecular/structural/functional changes in the tumor microenvironment to changes measured with in vivo imaging, and develop well-?validated computational biology models of antiangiogenic resistance in breast cancer. Since such multiscale angiogenesis data and models do not currently exist, we have proposed to develop them in this application. Therefore, our goal is to elucidate the mechanisms of antiangiogenic resistance in breast cancer and develop imaging biomarkers to identify patients that could benefit most from antiangiogenic agents. Guided by compelling preliminary data, we will pursue three Specific Aims: (1) To characterize angiogenesis and metastatic burden in a human breast cancer model with multiscale imaging; (2) To develop a multiscale image-based computational model of antiangiogenic resistance in breast cancer; and (3) To determine if treatment with a non-VEGF targeted antiangiogenic/anti-tumorigenic peptide can circumvent resistance.
Under Aim1, we will create co-registered, quantitative angiogenesis data at complementary spatial scales, over time, by combining in vivo MRI, ex vivo magnetic resonance microscopy (?MRI) ex vivo micro-CT (?CT) and laser scanning confocal microscopy (LSCM). Multiscale imaging will relate in vivo angiogenic changes to alterations in tumor microvasculature and angiogenic protein expression.
Under Aim2, we will use multiscale imaging data from Aim1 to develop a computational model of antiangiogenic resistance that is comprehensively validated in an experimental breast cancer xenograft. We will vary model parameters implicated in antiangiogenic resistance to identify changes in the tumor microenvironment that can be exploited as clinical biomarkers of antiangiogenic resistance in breast cancer.
Under Aim3, we will treat a human breast cancer model with a non-VEGF targeted multimodal antiangiogenic/anti-tumorigenic peptide to determine if targeting multiple pathways can overcome antiangiogenic resistance in breast cancer. The approach is innovative because it blends cutting-edge advances in multiscale imaging, multiscale computational modeling and biomimetic peptides. This approach has the potential to impact 'systems biology' investigations of other cancers and diseases involving the pathological vasculature. The proposed research is significant because we expect to: (i) elucidate the mechanisms via which antiangiogenic resistance develops in breast cancer patients; (ii) identify potential imaging-based biomarker of antiangiogenic resistance, and (iii) test therapies that circumvent antiangiogenic resistance in breast cancer. Ultimately, such knowledge has the potential to identify new therapeutic strategies and reduce mortality from metastatic breast cancer.

Public Health Relevance

The proposed research is relevant to public health because there is a crucial need to identify those patients with metastatic breast cancer that are most likely to respond to antiangiogenic drugs. The proposed research is relevant to the NIH's mission because elucidating the mechanisms of antiangiogenic drug resistance in metastatic breast cancer will help develop new therapies and clinical biomarkers for ameliorating the suffering of these patients Our multiscale image-based computational modeling approach is consistent with NIH's commitment to transforming medicine through discovery.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA196701-01
Application #
8941820
Study Section
Medical Imaging Study Section (MEDI)
Program Officer
Baker, Houston
Project Start
2015-07-01
Project End
2020-06-30
Budget Start
2015-07-01
Budget End
2016-06-30
Support Year
1
Fiscal Year
2015
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21205
Norton, Kerri-Ann; Jin, Kideok; Popel, Aleksander S (2018) Modeling triple-negative breast cancer heterogeneity: Effects of stromal macrophages, fibroblasts and tumor vasculature. J Theor Biol 452:56-68
Bar-Shir, Amnon; Alon, Lina; Korrer, Michael J et al. (2018) Quantification and tracking of genetically engineered dendritic cells for studying immunotherapy. Magn Reson Med 79:1010-1019
Hadjiabadi, Darian H; Pung, Leland; Zhang, Jiangyang et al. (2018) Brain tumors disrupt the resting-state connectome. Neuroimage Clin 18:279-289
O'Connor, James P B; Aboagye, Eric O; Adams, Judith E et al. (2017) Imaging biomarker roadmap for cancer studies. Nat Rev Clin Oncol 14:169-186
Pak, Rebecca W; Hadjiabadi, Darian H; Senarathna, Janaka et al. (2017) Implications of neurovascular uncoupling in functional magnetic resonance imaging (fMRI) of brain tumors. J Cereb Blood Flow Metab 37:3475-3487
Norton, Kerri-Ann; Wallace, Travis; Pandey, Niranjan B et al. (2017) An agent-based model of triple-negative breast cancer: the interplay between chemokine receptor CCR5 expression, cancer stem cells, and hypoxia. BMC Syst Biol 11:68
Penet, Marie-France; Kakkad, Samata; Pathak, Arvind P et al. (2017) Structure and Function of a Prostate Cancer Dissemination-Permissive Extracellular Matrix. Clin Cancer Res 23:2245-2254
Krishnamachary, Balaji; Stasinopoulos, Ioannis; Kakkad, Samata et al. (2017) Breast cancer cell cyclooxygenase-2 expression alters extracellular matrix structure and function and numbers of cancer associated fibroblasts. Oncotarget 8:17981-17994
Fortenberry, Yolanda M; Brandal, Stephanie M; Carpentier, Gilles et al. (2016) Intracellular Expression of PAI-1 Specific Aptamers Alters Breast Cancer Cell Migration, Invasion and Angiogenesis. PLoS One 11:e0164288
Cebulla, J; Huuse, E M; Pettersen, K et al. (2015) MRI reveals the in vivo cellular and vascular response to BEZ235 in ovarian cancer xenografts with different PI3-kinase pathway activity. Br J Cancer 112:504-13

Showing the most recent 10 out of 12 publications